Zai Lab Limited Unsponsored ADR

ZLAB Healthcare Biotechnology

Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024. In the quarter to June 2026, revenue fell 3.33%, EPS fell 24.3%, free cash flow fell 84.4% and total debt rose 36.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

23.25 0.26 −1.11%
Market cap
$2.7B
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
4/9
Altman Z
−0.24
Beneish M
−2.35
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
8.46 4.20 4.60 4.72
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(116.56) (74.25) (174.87) (33.47)
P/B ratio
4.91 2.70 3.15 3.50
EV/Sales
7.07 2.93 3.39 3.65
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(14.84) (8.21) (11.57) (10.11)
Current Ratio
2.87 2.45 2.40 2.13
Net Debt/EBITDA
13.28 8.75 8.19 6.50
Debt/Equity
0.27 0.29 0.32 0.39
Earnings Yield
(5.75%) (9.13%) (8.61%) (9.00%)
Free Cash Flow Yield
(5.63%) (8.49%) (6.37%) (7.65%)
Free Cash Flow per Share
(0.33) (0.25) (0.31) (0.58)
Book value per Share
6.90 6.53 5.98 5.43
Free Cash Flow
(36.09) (27.32) (34.20) (64.82)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates